Immune checkpoint inhibitors have become the standard for advanced lung cancer treatment, but their effect on the prevention of lung cancer metastasis is still unclear. T-cell receptors (TCRs) are key "signal sensors" that recognize neoantigens on the surface of cancer cells. This review summarizes the research progress of TCR-T cell therapy in the prevention and treatment of lung cancer from the perspective of the diversity of TCR repertoire and the mechanism of tumor antigen recognition, in order to improve the efficacy of the prevention and treatment of lung cancer metastasis.